STS数据库:临床IIIA-N2期肺癌的手术治疗现状
该研究基于STS胸外科数据库2002至2012年数据,分析了3319例临床IIIA-N2期肺癌手术患者的管理模式。结果显示54%患者直接手术,46%接受诱导治疗,直接手术组43%存在淋巴结过度分期;两组手术死亡率相似,诱导治疗后切除的5年生存率为35%。
要点
- 临床IIIA-N2肺癌手术管理异质性大,诱导治疗比例不足一半。
- 直接手术组43%出现淋巴结过度分期(cN2→pN0/N1)。
- 诱导治疗后切除的5年生存率为35%,手术死亡率与直接手术相当。
核心结论
- STS外科医生治疗以肺叶切除为主的cIIIA-N2肺癌可获得良好的短期和长期结果。
研究设计与样本
- 回顾性数据库研究,查询STS-GTSD 2002至2012年cIIIA-N2肺癌手术患者,部分>65岁患者链接Medicare数据。
主要发现
- 共纳入3319例手术管理的cIIIA-N2患者,其中1784例(54%)直接手术,1535例(46%)接受诱导治疗。
- 93%患者有PET扫描记录,51%在STS-GTSD中编码为接受有创纵隔分期。
- 直接手术组淋巴结过度分期(cN2→pN0/N1)占43%。
- 肺叶切除占69%,全肺切除占11%。
临床怎么用
- 临床IIIA-N2肺癌手术决策需注意影像学假阳性导致的过度分期,并应评估诱导治疗的适用性。
局限性
- 研究为回顾性数据库分析,可能存在编码偏倚和未校正混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of surgical resection in patients with clinical stage IIIA-N2 positive (cIIIA-N2) lung cancer is controversial, partly because of the variability in short- and long-term outcomes. The objective of this study was to characterize the management of cIIIA-N2 lung cancer in The Society of Thoracic Surgeons General Thoracic Surgery Database (STS-GTSD). METHODS: The STS-GTSD was queried for patients who underwent operations for cIIIA-N2 lung cancer between 2002 and 2012. A subset of patients aged older than 65 years was linked to Medicare data. RESULTS: Identified were 3,319 surgically managed, cIIIA-N2 patients, including 1,784 (54%) treated with upfront resection (treatment naïve upfront surgery group, and 1,535 (46%) with induction therapy. A positron emission tomography scan was documented in 93% of patients, and 51% of patients were coded in STS-GTSD as having undergone invasive mediastinal staging. Nodal overstaging (cN2→pN0/N1) was observed in 43% of upfront surgery patients. Lobectomy was performed in 69% of patients and pneumonectomy in 11%. Operative mortality was similar between patients treated with upfront surgery (1.9%) and induction therapy (2.5%, p = .2583). The unadjusted Kaplan-Meier estimate of 5-year survival of cIII-N2 patients treated with induction therapy then resection was 35%. CONCLUSIONS: STS surgeons achieve excellent short- and long-term results treating predominantly lobectomy-amenable cIIIA-N2 lung cancer. However, prevalent overstaging and abstention from induction therapy suggest "overcoding" of false positives on imaging or variable compliance with current guidelines for cIIIA-N2 lung cancer. Efforts are needed to improve clinical stage determination and guideline compliance in the GTSD for this cohort.
引用
- Boffa D, Fernandez FG, Kim S, et al. Surgically Managed Clinical Stage IIIA-Clinical N2 Lung Cancer in The Society of Thoracic Surgeons Database. Ann Thorac Surg. 2017. PMID: 28527969. doi:10.1016/j.athoracsur.2017.02.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。